Skip to main content

Table 3 The incidence of adverse events, serious adverse events and withdrawal due to adverse events

From: Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

OutcomeNo.of SRsNo.of original studiesNo.of cases/controlsFollow-up range (weeks)Estimate (95%CI)P-value95%PII2(P*)Egger’s P value
Adverse events
 aliskiren 75 mg vs placebo15742/7408–130.96 [0.84–1.08]0.48[0.78–1.17]0% (0.56)0.853
 aliskiren150mg vs placebo1101785/16398–260.99 [0.90–1.08]0.77[0.89–1.10]0% (0.65)0.43
 aliskiren300mg vs placebo191461/14788–261.02[0.93–1.12]0.68[0.91–1.15]0% (0.47)0.876
 aliskiren600mg vs placebo13499/49481.24 [1.07–1.43]0.004[0.49–3.13]0% (0.88)0.083
 aliskiren vs ARBs1NRNR4–80.98 [0.89–1.08]0.68NRNRNR
 aliskiren vs lorsartan1NRNR4–81.03 [0.79–1.35]0.83NRNRNR
 aliskiren vs valsartan1NRNR80.92[0.81–1.05]0.2NRNRNR
 aliskiren vs irbesartan1NRNR7–81[0.81–1.23]0.99NRNRNR
 aliskiren vs ACEIs12514/5088–261[0.89–1.11]0.93NA0%NA
 aliskiren vs Amlodipine12513/4928–320.99 [0.81–1.11]0.92NA37%NA
 aliskiren vs HCTZ11183/17680.95 [0.74–1.22]0.68NANANA
 aliskiren vs atenolol11231/231120.88 [0.72–1.08]0.23NANANA
Serious adverse events
 aliskiren vs placebo183633/16838–260.75 [0.27–2.05]0.57[0.07–7.71]32%(0.17)0.811
 aliskiren vs ARBS1NRNR4–80.72 [0.36–1.46]0.36NRNRNR
 aliskiren vs lorsartan1NRNR4–80.33 [0.01–8.18]0.5NRNRNR
 aliskiren vs valsartan1NRNR80.63 [0.09–4.43]0.65NRNRNR
 aliskiren vs irbesartan1NRNR7–80.55[0.18–1.67]0.29NRNRNR
Withdrawal due to adverse events
 aliskiren 75 mg vs placebo15821/8178–130.69 [0.37–1.29]0.24[0.25–1.90]0%(0.52)0.008
 aliskiren150mg vs placebo171161/11548–260.37[0.16–0.84]0.02[0.05–2.75]38%(0.14)0.065
 aliskiren300mg vs placebo16984/10018–260.60 [0.34–1.06]0.08[0.21–1.74]12%(0.34)0.365
 aliskiren600mg vs placebo11166/16580.14 [0.03–0.62]0.009NANANA
 aliskiren vs ARBs1NRNR4–80.82 [0.54–1.25]0.35NRNRNR
 aliskiren vs lorsartan1NRNR4–80.76[0.28–2.08]0.6NRNRNR
 aliskiren vs valsartan1NRNR80.89 [0.50–1.58]0.69NRNRNR
 aliskiren vs irbesartan1NRNR7–80.73[0.33–1.61]0.43NRNRNR
 aliskiren vs ACEIs231145/9528–360.76 [0.45–1.28]0.3[0.00–149.77]50%(0.13)0.953
 aliskiren vs Amlodipine12513/4928–320.42 [0.08–2.30]0.32NA65%NA
 aliskiren vs HCTZ11183/17681.92 [0.59–6.27]0.28NANANA
 aliskiren vs atenolol11231/231120.6 [0.22–1.62]0.31NANANA
  1. Notes: Type of metric for comparisons: RR (Risk ratio)
  2. Abbreviations: NA Not Accessible, NR Not Report, SA Systematic review